The increased expression of the Disintegrin and Metalloprotease ADAM12 has been associated with human cancers, however its role remain unclear. We have previously reported that ADAM12 expression is induced by the transforming growth factor, TGF-β and promotes TGF-β-dependent signaling through interaction with the type II receptor of TGF-β. Here we explore the implication of ADAM12 in TGF-β-mediated epithelial to mesenchymal transition (EMT), a key process in cancer progression. We show that ADAM12 expression is correlated with EMT markers in human breast cancer cell lines and biopsies. Using a non-malignant breast epithelial cell line (MCF10A), we demonstrate that TGF-β-induced EMT increases expression of the membrane-anchored ADAM12L long form. Importantly, ADAM12L overexpression in MCF10A is sufficient to induce loss of cell-cell contact, reorganization of actin cytoskeleton, up-regulation of EMT markers and chemoresistance. These effects are independent of the proteolytic activity but require the cytoplasmic tail and are specific of ADAM12L since overexpression of ADAM12S failed to induce similar changes. We further demonstrate that ADAM12L-dependent EMT is associated with increased phosphorylation of Smad3, Akt and ERK proteins. Conversely, inhibition of TGF-β receptors or ERK activities reverses ADAM12L-induced mesenchymal phenotype. Together our data demonstrate that ADAM12L is associated with EMT and contributes to TGF-β-dependent EMT by favoring both Smad-dependent and Smad-independent pathways.
Introduction
ADAM12 is a member of the ADAM (a metalloprotease and disintegrin) protein family, a class of cell surface glycoproteins whose functions have been implicated with cell adhesion,
Material and Methods

Tissue Samples
Human tissue samples were obtained from the Biological Resource Center of Centre Léon Bérard (http://www.centreleonberard.fr/) after approval by the Comité de Protection des Personnes Lyon-Est and by the institutional review board and ethics committee of Centre Léon Bérard (French agreement number: DC-2008-99). Patient gave written informed consent after acquisition of information from the physicians. Tissue specimens were collected before any therapy from 89 patients suffering from breast cancer diagnosed between 1993 and 2001. The mean patient age at surgery was 51 + 11years (range, 27-83 years). The mean size of tumors was 3.9 + 3.1 cm and forty-four percent of the patients showed metastasis at the time of diagnosis.
Cell Culture and Treatment
The human breast cancer cell lines (S1 Table) were generously provided by Dr. R. Rimokh (CRCL, Lyon) and grown in different cell culture media as described [33] . The mammary epithelial cell line MCF10A was obtained from American Type Culture Collection and MCF10A cells infected with LXSN-K-RasV12 or an empty vector [34] were provided by Dr BH Park (Baltimore, MD, USA). Primary human mammary epithelial cells (HMEC) infected with a retrovirus carrying hTERT, H-Ras-V12 Ras and SV40 large T antigen were provided by Dr RA Weinberg (Cambridge, MA, USA) [35] . HMECs immortalized by hTERT and Ras were designated HMEC-TR. HMECs immortalized by SV40 large T, hTERT and Ras were designated HMEC-LTR. The human mammary epithelial cells (MCF10A) were cultured in (1:1) DMEM: F12 medium supplemented with 5% horse serum, 100 ng/ml cholera toxin, 20 ng/ml EGF, 500 ng/ml hydrocortisone, and 10 μg/ml insulin. Epithelial mesenchymal cell transition was induced by treatment with recombinant TGF-β1 (Peprotech, France) at 5 ng/ml. The expression vectors for GFP-ADAM12L, ADAM12S and the protease inactive mutant ADAM12-L-E351Q, were a gift from Dr. U. Wewer (Biotech Research & Innovation Centre (BRIC), University of Copenhagen). To generate lentiviral constructs, full length GFP-ADAM12L was subcloned into the pLVX-Puro vector (Clontech) and ADAM12L-E351Q and ADAM12S were subcloned into the pLVX-AcGFP1-N1 vector (Clontech). To produce viral particles, HEK293T cells were transfected with lentiviral constructs and the packaging vectors pMD2.G and psPAX2 using calcium phosphate transfection. At 48 hours after transfection, supernatant containing lentiviruses were collected and centrifugated at 130000g for 2h at 4°C on a 20% sucrose cushion to concentrate viruses. MCF10A cells were incubated with lentiviral particles for 48h Table 1 . List of oligonucleotide primer pairs used in real time RT-PCR.
Name
Sense Anti-sense ADAM12L CAC CAT TGA AAA ACT AAG GTG TGT GAG CCT GAC AGG GTT GGA AG ADAM12S CTG GGC ACC TCC CTT CTG TGC TTC TGC TTG CCG GA Vimentin CCA AAC TTT TCC TCC CTG AAC C GTG ATG CTG AGA AGT TTC GTT GA N-cadherin GTG CAT GAA GGA CAG CCT ATG CCA TCT TCA TCC ACC TT E-cadherin GTC ATC CAA CGG GAA TGC A TGA TCG GTT ACC GTG ATC AAA A TGF-β TGC GCT TGA GAT CTT CAA ACA GGG CTA GTC GCA CAG ACC TC Twist GCA AGA TTC AGA CCC TCA AGC CTC CAT CCT CCA GAC CGA GA Fibronectin GAA GAG CGA GCC CCT GAT GGG GTC TTT TGA ACT GTG GA β-catenin AAA ATG GCA GTG CGT TTA G TTT GAA GGC AGT CTG TCG TA 18S CGC CGC TAG AGG TGA AAT TC TTG GCA AAT GCT TTC GCT C 
Relative Quantification of mRNA
Real-time quantitative PCR (RT-qPCR) was performed using the fluorescent dye SYBR Green methodology with the SybrTM Green I qPCRTM Core Kit (Eurogentec, Seraing, Belgium) and the ABI Prism 7700 (Perkin-Elmer, Foster city, CA, USA. The sequences of primer pairs are described in Table 1 .
Western Blotting
Cells lysates were subjected to SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (GE Healthcare, UK). The membranes were incubated for 1 hour in Trisbuffered saline containing 0.1% Tween 20 and 5% non-fat dry milk and incubated overnight with primary antibodies. The bound antibodies were visualized using horseradish peroxidaseconjugated antibodies against rabbit or mouse IgGs (DAKO, Les Ulis, France) using an enhanced chemiluminescence system (Millipore, Billerica, MA, USA). Antibodies were; ADAM12 polyclonal antibody from Sigma-Aldrich. Anti-α-phospho-p38 (Thr180/Tyr182), anti-p38 MAPK, anti-Smad2 (86F7); anti-phospho-Smad2 (Ser465/467), anti-Smad3, antiphospho-Smad3 (Ser423/425), anti-phospho-Akt (Ser473) (D9E), anti-Akt (C67E7), anti-phospho-ERK1/2 (T202/Y204) (E10), anti-ERK1/2 (137F5), anti-phospho-JNK (Thr183/Thr185) (G9), E-cadherin (24E10), N-cadherin, anti-cleaved caspase 3 (Asp175) (5A1E) and anti-Bid were from Cell Signaling (Saint Quentin en Yvelines, France). Anti-actin and anti-JNK were from Santa Cruz Biotechnology (CA, USA). Anti-vimentin (V9) was from Dako. ADAM12 enrichment from MCF10A cell lysates was performed using affinity chromatography on a HiTrap Con A column. Briefly protein extracts were homogenized in binding buffer (20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 0.05% Chaps). After several washes with the binding buffer, proteins were eluted with 20 mM Tris-HCl (pH 7.5), 500 mM NaCl, 0.2% Chaps and 0.5 M methyl a-D-mannopyranoside. Densitometry analyses were performed with ImageJ software.
Immunostaining and Imaging
To detect actin, E-cadherin and vimentin in MCF10A, cells were fixed with 4% paraformaldehyde for 15min and permeabilized with 0.1% Triton X-100 in PBS before incubation with rabbit E-cadherin antibody (Cell Signaling) followed by alexa 555-conjugated anti-rabbit (Cell Signaling), vimentin antibody (Dako) followed by alexa 555-conjugated anti-mouse (Cell Signaling) or rhodamine-phalloïdin (Interchim, Montluçon, France). The slides were washed, mounted and viewed using an automated LEICA DMRXA2 microscope.
Migration Assay
For Wound Healing assays, the confluent monolayer was scratched using a pipette tip and incubated with 2.5 μg/ml mitomycin without serum and images were captured using an automated LEICA DMRXA2 microscope at the indicated times. For Boyden chambers assays (Millipore, Molsheim, France), epithelial cells (3 × 10 5 cells per chamber) were added to the top chamber in low serum (1%)-containing medium. The bottom chamber was filled with low serum (1%)-containing medium. Cells were cultured for 24 h at 37°C. To quantify migration, cells were mechanically removed from the top side of the membrane using a cotton-tipped swab, and migrating cells from the reverse side were fixed with methanol and stained with Giemsa. For each experiment, five representative pictures were taken for each insert, then cells were lysed and absorbance at 560 nm correlated to the amount of Giemsa stain was measured.
Soft Agarose Colony Formation Assay
Anchorage-independent cell growth was determined by analyzing colony formation of cells in soft agar. Cells (1 × 10 4 ) were resuspended in 1 ml of top agar (MCF10A media containing 0.35% Noble agar (USB Corp., Cleveland, OH) warmed to 40°C). The cell suspension was layered onto 1 ml of set bottom agar (MCF10A media containing 0.5% Noble agar) in a 6-well plate. One milliliter of medium was added on the top agar and changed once per week to compensate for evaporation. Colonies greater than 100 cells were scored after 4 weeks.
Viability Assay
For cytotoxicity assays, cells (2.5×10 4 ) were seeded in 96-well plates. Cells were treated with cisplatin or FasL for the indicated time and cell viability was determined by the MTT assay. Absorbance was measured at 550nm on Spectramax microplate reader (Molecular Devices, Wokingham, UK), and percentage of viability was calculated as the absorbance ratio of treated to untreated cells.
Caspase-3/7 Activity
For cisplatin and FasL-induced toxicity experiments, caspase-3/7 activity was measured using 'SensoLyte Homogeneous AMC Caspase-3/7 Assay' kit (Anaspec, Le-Perray-en-Yvelines, France) following manufacturer's instructions. Briefly, cells were incubated with the caspases-3/7 substrate Asp-Glu-Val-Asp-7-amino-4-methylcoumarin (DEVD-AMC) for 1h at 37°C and cleavage of the substrate AMC by caspases was measured by spectrofluorometry (Molecular Devices) at 380/440nm (ex/em). Results were expressed as Vmax.
Bioinformatic Tool and Database
Gene array data were extracted from the genomics data repository, Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/). Text mining analysis was performed using CoPub tool (http://services.nbic.nl/copub5).
Results
ADAM12 Is Associated with the Expression of Mesenchymal Markers in Breast Cancer Cell Lines and Human Breast Tumors
To evaluate the putative implication of ADAM12 in EMT, we first performed in silico analyses using transcriptional data previously reported for breast cancer cell lines [36, 37] . Cell lines have been shown to cluster into basal-like and luminal expression subsets and the basal-like cell lines resolved into two distinctive clusters, Basal A and Basal B. [38] . Because Basal B cells have a mesenchymal-like appearance while Basal A cells exhibit luminal-like morphology, we searched for genes differentially expressed between Basal B cell lines and the more differentiated Luminal and Basal A cell lines. For that purpose, microarray data were extracted from Gene Expression Omnibus (GEO) database repository and we performed new analyses using SAM (Significance Analysis of Microarrays) tool. As detailed in S2 Table, we identified 665 genes overexpressed in Basal B cells including ADAM12 and EMT-associated genes such as CDH2, SNAI2 and VIM. To further characterize the relationships between these genes, we performed a text mining analysis of the 100 most statistically significant genes to build clusters of co-cited genes. As shown in Fig 1A, ADAM12 is linked with several members of TGF-β signaling such as TGFB1 itself, the receptor TGFBR2 and the antagonizing protein FSTL3 but also with the metalloproteases MMP2 and ADAM19, the N-cadherin (CDH2), the fibroblast activation protein FAP, the actin regulatory protein CAPG and a member of the hyaluronan-binding protein family, TNFAIP6.
To confirm these data, we performed new RT-PCR experiments on an independent set of 20 breast cancer cell lines. We observed again a strong correlation between expression of ADAM12L and ADAM12S with expression of N-cadherin (R = 0.75 and R = 0.64, p<0.001) and vimentin (R = 0.58 and R = 0.41, p<0.001) but not with that of E-cadherin ( Fig 1B) . In agreement with the meta-analyses, we found increased expression of ADAM12L and ADAM12S in Basal B cell lines compared with Luminal/BasalA cell lines. To further validate the association of ADAM12 expression with EMT, we used primary human mammary epithelial cells (HMECs), immortalized by hTERT and Ras (HMEC-TR) or by SV40 large T, hTERT and Ras (HMEC-LTR) that we treated with TGF-β to induce EMT as previously described [39] . We showed again that ADAM12 expression is highly induced in TGF-β-treated cells with mesenchymal phenotype and this expression is correlated with vimentin and N-cadherin expression (S1 Fig) .
To investigate the physiological relevance of these observations, we next analyzed the expression of ADAM12 in 79 breast tumor samples. Steady-state ADAM12L and ADAM12S, N-cadherin, vimentin, TGF-β and E-cadherin mRNA levels were measured by real-time PCR. As shown in Fig 2A, expression of ADAM12L and ADAM12S was significantly correlated with that of N-cadherin (R = 0.52 and R = 0.44, p<0.001), vimentin (R = 0.55 and R = 0.70, p<0.001) and TGF-β (R = 0.61 and R = 0.46, p<0.001) but not with that of E-cadherin. As previously demonstrated in liver cancer [6] , ADAM12L and ADAM12S mRNA levels were highly correlated (R = 0.79, p<0.001). Importantly, the increased expression of ADAM12L (0.8±0.9 versus 1.2±1.1, p<0.05) and ADAM12S (0.7±0.9 versus 1±1.3, p<0.05) in breast samples was associated with the presence of metastases supporting evidences for the involvement of ADAM12 in human tumor aggressiveness (Fig 2B) . Together, these data demonstrated that expression of ADAM12 is correlated with the expression of EMT markers in breast cancers and confirmed the association of ADAM12 expression with aggressiveness.
ADAM12 Expression Is Induced in Epithelial Cells that Undergo TGF-β-Dependent EMT
To characterize the dynamics of ADAM12 expression during EMT, we used the non-transformed human breast mammary epithelial cell line MCF10A. As expected, TGF-β treatment rapidly induced the expression of the mesenchymal marker vimentin and reduced the expression of the epithelial marker E-cadherin ( Fig 3A) . ADAM12 which is not expressed in epithelial cells at the basal state (time 0) is detected at 48 hours and significantly increased 96 hours after the onset of TGF-β stimulation. Western blotting identified expression of a 110kDa band corresponding to the ADAM12L preform, the mature form being undetectable in these conditions. As control, epithelial cells treated with the TβRI inhibitor, SB431542 did not show mesenchymal transition and ADAM12L expression. Using immunofluorescence experiments, we confirmed decrease of E-cadherin, increase of vimentin staining and actin fibers formation after TGFβ treatment (S2 Fig) .
To confirm the association of ADAM12L expression with EMT in mammary epithelial MCF10A cells, we showed that Kras-transformed MCF10A cells which display EMT phenotype highly expressed ADAM12L (Fig 3B) . Because TGF-β-induced EMT has been associated with changes in TGF-β-signaling pathways [40] , we next analyzed Smad-dependent and Smad-independent pathways in our model. As shown in Fig 3C , TGF-β treatment induced both the Smaddependent pathway characterized by the phosphorylation of Smad2 and the Smad-independent pathways characterized by the phosphorylation of Akt and p38 MAPK. Our results demonstrate that the expression of ADAM12L is induced in non-malignant breast epithelial cells stimulated by TGF-β suggesting that ADAM12L is a new marker for TGF-β-dependent EMT.
Overexpression of ADAM12L Induces Mesenchymal Phenotype in MCF10A Mammary Epithelial Cells
To explore the role of ADAM12L in EMT, we exogenously expressed GFP-ADAM12L C-terminal fusion protein in MCF10A cells using a lentiviral expression system. As illustrated in Fig 4A and 4B, enforced expression of ADAM12L in MCF10A cells triggered cellular morphologic changes. ADAM12L-overexpressing MCF10A cells exhibited a spindle shape, fibroblast-like phenotype with accumulation of stress fibers and loss of cell-cell contact assessed by dramatic reduction of E-cadherin and increased vimentin immunostaining. By contrast, MCF10A control cells retained an epithelial phenotype that include rounded-shaped cells, high E-cadherin and low vimentin labeling, cortical staining of actin and cell-cell contacts. To investigate the induction of EMT transcriptional program in ADAM12L-overexpressing MCF10A cells, we performed gene expression analyses. We showed a decrease in mRNA levels of the epithelial markers that include E-cadherin and β-catenin and an increase in mRNA levels of mesenchymal markers that include N-cadherin, vimentin, fibronectin and the transcriptional repressors Zeb1 and Twist (Fig 4C) . These results were confirmed by western blotting, showing that E-cadherin is strongly down-regulated whereas vimentin is up-regulated in ADAM12L-overexpressing MCF10A (Fig 4D) . Importantly, silencing ADAM12 expression in ADAM12L-overexpressing MCF10A reverse the expression of the epithelial marker, E-cadherin (Fig 4E and 4F) .
Because we have previously shown that ADAM12 overexpression modulates Smad-dependent TGF-β and PI3K/Akt pathways [22, 24] , we investigated the activation of signaling pathways in ADAM12L-overexpressing MCF10A cells. As illustrated in Fig 4G, ADAM12L overexpressing cells showed significant increase amount of phosphorylated forms of Smad3 ( Ser423/Ser425 P-Smad3), Akt ( Ser473 P-Akt) and ERK ( Thr202/Tyr204 P-ERK), while phosphorylation of Smad2 ( Ser465/Ser467 P-Smad2), p38 ( Thr180/Tyr182 P-p38) and JNK ( Thr183/Thr185 P-JNK) was not significantly modified (not shown). Interestingly the increase in Smad3 phosphorylation was always more pronounced than for Smad2 suggesting that the effect of ADAM12L is more likely Smad3-specific. In accordance with this, Smad3 but not Smad2 has been shown critical to induce TGF-β-mediated EMT [41, 42] . Note that the expression of both immature (137 kDa) and activated (117 kDa) GFP-ADAM12L forms was detected in ADAM12L-overexpressing MCF10A cells suggesting that the maturation process is functional in these cells.
ADAM12L-Induced EMT Is Independent of Its Catalytic Activity but Requires Its Cytoplasmic Tail
To further explore the molecular mechanisms underlying this novel modulation of EMT by ADAM12L, we next compared MCF10A cells which exogenously expressed either ADAM12L or the catalytically deficient ADAM12-E351Q mutant or the short ADAM12S form. As illustrated in Fig 5A , the catalytically deficient ADAM12-E351Q mutant induced a mesenchymal phenotype to an extent similar to that of wild-type ADAM12L suggesting that proteolytic activity of ADAM12L is not required for EMT induction. In contrast, ADAM12S-overexpressing MCF10A cells retained an epithelial phenotype demonstrating that ADAM12L is specifically involved in EMT. To validate these observations, we next quantified the amount of the epithelial marker E-cadherin and the mesenchymal marker vimentin. In accordance with the mesenchymal phenotype, we found a significant increased expression of vimentin and a decreased expression of E-cadherin in ADAM12L-and ADAM12-E351Q mutant-overexpressing cells (Fig 5B) . In contrast, E-cadherin and vimentin expression in ADAM12S-overexpressing cells was similar to that of control cells demonstrating the differential role of the two forms of ADAM12. To further investigate the mechanisms involved in ADAM12L-induced EMT, we generated MCF10A cells overexpressing cytoplasmic domain deletion mutant (ADAM12L-Δcyto). As shown in Fig 6 , the cytoplasmic tail is required for the ADAM12L-induced EMT since overexpression of the deletion mutant failed to induce a mesenchymal phenotype but retained high cadherin expression and cell-cell contacts. As previously reported, ADAM12L-Δcyto is targeted to the cell membrane [43] .
Overexpression of ADAM12L Induces Chemoresistance
Because EMT phenotype has been associated with chemoresistance, we investigated the effects of cisplatin on ADAM12L-overexpressing cells. As shown in Fig 7A, ADAM12L ADAM12 and TGF-β-Induced EMT overexpression confers resistance to cisplatin-induced death. This effect is correlated with a decrease in caspase 3/7 activity. In accordance with these results, we showed that ADAM12L-overexpressing cells are protected against FasL-induced apoptosis supporting the implication of ADAM12L in death resistance ( Fig 7B) . As expected, ADAM12LΔCyto-and ADAM12S-overexpressing cells did not show significant resistance to cisplatin while ADAM12L-E351Q-overexpressing cells are chemoresistant to a similar extend that of ADAM12L-overexpressing cells (Fig 7C) . This effect of ADAM12L is specific of the non-cancerous human breast epithelial cell line MCF10A since overexpression of ADAM12L in MCF7, MDA-MB231 and MDA-MB436 cells did not induce cisplatin chemoresistance (S3A Fig) . Accordingly, overexpression of ADAM12L in these breast cancer cell lines did not modify E-cadherin and vimentin expression (S3B Fig) . Together, these results demonstrate that expression of ADAM12L in the non-malignant breast epithelial cell line MCF10A induces a mesenchymal phenotype linked to the acquisition of chemoresistance. Of note, these effects are associated with a decrease in cell proliferation without changes in migration and invasion (S4 Fig). 
ADAM12L Expression Contributes to EMT through TGF-β ReceptorDependent and Independent Pathways
Because ADAM12L expression is induced during TGF-β-induced EMT (Fig 3) and because ADAM12L overexpression is sufficient to induce EMT (Fig 4) , we next investigated the overlaps between TGF-β and ADAM12L effects in promoting EMT. For that purpose, we compared the effect of TGF-β treatment of ADAM12L-overexpressing MCF10A cells with that of control cells. As illustrated in Fig 8A, we observed a stronger decrease in E-cadherin and a higher increase in vimentin expression in ADAM12L-overexpressing cells compared to control cells. This effect is sensitive to the concentration of TGF-β for E-cadherin expression while the amount of vimentin between ADAM12L-overexpressing cells and controls differed only for weak TGF-β concentration since TGF-β treatment rapidly saturated the induction of vimentin (Fig 8B) . These data demonstrate that the presence of ADAM12L in epithelial MCF10A cells enhances the effect of TGF-β in inducing EMT phenotype. Note that blocking TGF-β-dependent induction of endogenous ADAM12L expression in MCF10A slightly but not significantly prevent the E-cadherin decrease and vimentin increase upon TGF-β stimulation (S5A and S5B  Fig) . In addition, inhibiting ADAM12 expression in MDA-MB231 and MDA-MB436 mesenchymal cells that express endogenous ADAM12 did not reverse their mesenchymal phenotype (S5C Fig). Together these data suggest that ADAM12L contributes but is not essential to TGF-β-induced EMT in cultured MCF10A cells.
In order to further evaluate the overlap between ADAM12L and TGF-β effects, we investigated whether the inhibition of TGF-β signaling decreased EMT phenotype induced by ADAM12L. For that purpose, cells were treated with a selective inhibitor of TGFβR1 (SB431542) that blocks the initialization of TGF-β dependent signaling pathways at the receptor level. As shown in Fig 9A, SB431542 treatment of ADAM12L-overexpressing cells induced a significant increase in E-cadherin expression (2 ± 0.2 fold, p<0.05) and a slight decrease in vimentin expression (0.74 ± 0.1 fold, p<0.05) suggesting that inhibition of TGF-β receptors partially restored the epithelial phenotype. The efficiency of SB431542 treatment was shown by the decrease in Smad2 phosphorylation. Because expression of ADAM12L is associated with changes of Smad-independent signaling pathways (Fig 4G) , we investigated the effects of ERK and PI3K inhibitors on ADAM12L-induced mesenchymal phenotype. ADAM12L-overexpressing MCF10A cells were incubated with either a highly selective inhibitor of MEK/ERK kinases, U0126 or the specific inhibitor of phosphoinositide 3-kinase (PI3K), Wortmannin. As shown in Fig 9B and S6 Fig, U0126 treatment induced a dramatic decrease in vimentin and N-cadherin and an increase in E-cadherin. Unlike U0126, treatments with Wortmannin did not reverse EMT phenotype in ADAM12L-overexpressing cells (Fig 9C and S6 Fig) . Together, these results provide strong evidence for the implication of TGFβR and MEK/ERK-dependent pathways in ADAM12L-induced mesenchymal phenotype.
Discussion
Epithelial mesenchymal transition is a complex cell-biological program whereby epithelial tumor cells loose polarity and cell-cell adhesion to acquire mesenchymal phenotype. Using transcriptomic data from a large panel of breast cancer cell lines, we demonstrated that ADAM12 clustered with EMT gene signature suggesting that ADAM12 is a component of EMT protein networks. We further showed that expression of ADAM12 is correlated with expression of EMT markers in human breast cancer samples and the presence of metastases. The association of ADAM12 with breast cancer aggressiveness is in accordance with the induction of metastasis in vivo by ADAM12-overexpressing breast cell lines [3, 15] and the MCF10A cells overexpressing GFP-ADAM12 were treated (+) or not (-) with (A) the selective inhibitor of TGFβRI, SB431542 (10μM), (B) a highly selective inhibitor of both MEK1 and MEK2, U0126 (10μM), and (C) the PI3K inhibitor, Wortmannin (10μM) for 72 hours. The expression of vimentin and E-cadherin was analyzed by western blot and quantified by densitometry. Data are expressed as mean±SD from four independent experiments (*, p<0.05; **, p<0.01).
doi:10.1371/journal.pone.0139179.g009
ADAM12 and TGF-β-Induced EMT association of ADAM12 with metastases in triple-negative breast cancer [44] . Additionally ADAM12 expression has been recently identified in transcriptomic data from claudin-low tumors [45] which have been previously associated with EMT core signature [46] . Together these studies point out ADAM12 as a new EMT marker.
ADAM12 Is Associated with TGF-β Dependent EMT
ADAM12 has been identified as a regulator of mesenchymal cell differentiation while its expression has been mainly associated with cancer epithelial cells suggesting that increased ADAM12 expression in tumor cells is associated with dedifferentiation of epithelial cells towards mesenchymal phenotype. This point was clearly demonstrated by our results showing that treatment of the non-malignant breast epithelial cell line MCF10A with TGF-β induced EMT and ADAM12 expression. In support of this, ADAM12 expression has been identified as a gene primarily induced in MCF10A cells silenced for TIF1γ, a negative regulator of TGF-β transcriptional activity, and characterized by EMT phenotype [47] . Similarly, down-regulation of SnoN, a negative regulator of TGF-β signaling, has been shown to enhance both EMT in lung and breast cancer cells [48] and TGF-β-induced expression of ADAM12 [49] . Interestingly, there is a direct relationship between ADAM12 expression and cell differentiation processes regulated by TGF-β. On one hand, TGF-β inhibits mesenchymal cell differentiation promoting progenitor cells proliferation and ADAM12 is mainly associated with undifferentiated proliferative state of mesenchymal cells such as chondrocytes [50] , adipocytes [51] , myoblasts [52] and osteoblasts [53] . On the other hand, TGF-β acts as a major inducer of EMT and we now demonstrate that TGF-β-induced ADAM12L expression in epithelial cells is correlated with EMT process. Of note, EMT is associated with the gain of epithelial stem-cell properties [54] and recent findings demonstrated functional association of ADAM12 with TGF-β-dependent stem cell differentiation [55] and identified ADAM12 as a marker of embryonic stem cells [56] thereby suggesting that ADAM12 might be an important player in stem cell differentiation.
The Long but Not the Short ADAM12 Form Induces Mesenchymal Phenotype
A major finding in the present study is the demonstration that ADAM12L expression in nonmalignant human breast epithelial cell line MCF10A induces phenotypical changes associated with EMT that include loss of cell-cell contact, accumulation of stress fibers and increased expression of specific markers. Importantly we further demonstrate that ADAM12L expression in epithelial cells confers chemoresistance, a known feature of mesenchymal cells. Unlike ADAM12L, the overexpression of ADAM12S does not induce changes in epithelial phenotype. These data are in accordance with the differences previously reported between the long and short forms. ADAM12L but not ADAM12S transcripts were found overexpressed in human non-small-cell lung carcinomas [11] and inversely associated with survival rate in lung adenocarcinoma patients [57] . In human breast cancer, ADAM12L expression has been found higher in early-stage of tumorigenesis, both isoforms being induced in late-stage diseases [15] . Similarly, we show that expression of ADAM12L but not ADAM12S is induced within 48 hours in MCF10A stimulated by TGF-β supporting the hypothesis that ADAM12L is an earlier marker of tumor development. However, ADAM12L over-expression does not affect cell motility and does not induced proliferation of normal epithelial cell lines. Absence of changes in motility have been similarly reported in MCF7 breast cell line [15] and lung cancer cell lines [58] and no proliferation was reported in normal breast epithelial [59] . By contrast, ADAM12L overexpression has been shown to promote proliferation of bronchial epithelial immortalized cells [60] and small cell lung carcinoma cell lines [58] suggesting that the effect of ADAM12L depends on the differentiation state of cells.
Cooperative Effect of ADAM12L and TGF-β Signaling Pathways in EMT
The functional mechanism associating ADAM12 and TGF-β signaling is supported by our previous work showing that ADAM12 interacts with TβRII which recruits TβRI to induce TGF-β signaling pathways [24] . Numerous ADAM12 interacting proteins are required for TGF-β signaling-dependent EMT such as ILK, ITGB1, PIK3R1, Grb2, and Src. Here, we demonstrate for the first time that ADAM12L expression in MCF10A cells results in both phosphorylation of Smad3 and ERK, two key proteins involved in TGF-β-mediated EMT [42] [61] . Together our data support evidence for the involvement of ADAM12 in activation of pathways similar to that induced by TGF-β. In accordance with this hypothesis, we demonstrate that specific inhibitors of TβR1 (SB431542) and MEK/ERK pathway (U0126) can reverse ADAM12L-induced EMT suggesting that ADAM12L acts through the TGF-β receptor and involves ERK pathway in absence of TGF-β ligand. An interesting point is that the effects of ADAM12L and TGF-β ligand are additive thereby providing evidences for a cooperative role of ADAM12L during the course of TGF-β-induced EMT. Because ADAM12 expression is induced by TGF-β [6] [62] and that activation of signaling pathways occurs independently of TGF-β stimulation in ADAM12L-overexpressing cells, ADAM12L could induce ligand-independent activation of TGF-β receptors-dependent pathways. Similarly, changes of ADAM12-overexpressing cells toward mesenchymal-like phenotype could be associated with secretion of new potential ligands for TGF-β receptors. In support of this hypothesis, type I collagen which is produced by numerous mesenchymal cells and which regulates ADAM12 translocation to the membrane [26] has been shown to activates EMT through Smad3-dependent pathways in absence of TGF-β stimulation [63] .
To conclude, our present study establishes ADAM12 as a new EMT marker in human breast cancers. Importantly, expression of ADAM12L in non-malignant breast epithelial cells promotes EMT through TGF-β receptor-dependent pathways involving ERK phosphorylation. These findings support new functions for ADAM12L in cancer acting as a signaling molecule that contributes to the complexity of TGF-β signaling pathways in EMT process. 
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